Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
List view / Grid view
Legal & Compliance
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
A National Science and Technology Council and Office for Science and Technology Strategy will be established to aid the UK's scientific industry.
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
A summit will be held between the UK and CEPI to raise funds for vaccine research and development in a bid to avert future pandemics.
UK Health Secretary Matt Hancock has announced £37 million of funding for genomics and data projects to support the life sciences sector.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
Product hub: The world’s first BioPharma Lifecycle Management system – navigating your biopharma lifecycle
Here, we present IDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration and insight.
A report has been backed by eight industry leaders who say that updating R&D tax credit systems in the UK would release £4 billon of growth every year.
Researchers in Boston have repurposed their lab into a centre to test samples for COVID-19, releasing a blueprint of how to do so for other labs in the US.
Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.